Previous 10 | Next 10 |
Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet ® into the equine market by making IsoPet ® available to treat solid tumors in horses. The most common tumors are equoids and sarcom...
LOS ANGELES, CA / ACCESSWIRE / September 1, 2020 / Vivos Inc (OTCQB:RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will be presenting at the LD 500 investor conference on...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
Richland WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), We are excited to announce that based on the recommendation of our Medical Advisory Board, Vivos Inc has decided on treating inaccessible (non-resectable) cancerous lymph nodes, particularly in the head, neck, an...
Richland WA, July 30, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Interest in IsoPet therapy is increasing. Yesterday Vivos Inc treated “Mister Motto” a cat that the pet parents flew to the state of Washington from New York City. As interest and awareness conti...
Richland WA, July 22, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced it received the Grant of Protection for the Radiogel ™ trademark application in China. The mark is now officially registered in China until April 21, 2024, with the opportunity to extend for...
Richland WA, June 24, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel ™ for human therapy. Animal testing at the University of Missouri was completed in 2019. Since then we have been focusing on com...
Richland WA, June 10, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced that is has submitted an international application based on its patent submittal last June. This is part of the Patent Cooperation Treaty (PCT), which cover 153 countries. It allows 30 months for th...
Richland WA, May 29, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc Resumes IsoPet Animal Cancer Therapy After several months of virus-related stand-down IsoPet therapy has been scheduled for the week of June 20. Our East Coast Y-90 supplier, our Texas production site a...
Richland WA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos today announced that the University of Missouri College of Veterinary Medicine will be the first Isopet ® regional clinic. The Isopet ® therapy will now be included as a treatment option within th...
News, Short Squeeze, Breakout and More Instantly...
The Dow Jones index closed higher by over 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern ar...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...